BGA002 treatment induces a marked dose-dependent reduction of MYCN transcript, followed by a diminishment in N-Myc protein levels and accompanied by growth inhibition in SCLC cells (Figure 1A–C and Figure S1C). Here, MYCN is linked to small cell lung carcinoma.